Meanwhile, BMS is looking to expand Sotyktu beyond plaque psoriasis.

Source: https://medcitynews.com/2023/03/takeda-details-the-clinical-data-that-led-to-a-4b-deal-for-an-autoimmune-drug/

These are the company's aggressive M&A policy, which allowed it to acquire best-in-class drugs, an extremely high dividend yield exceeding 4.6%, high rates of Opdivo's label expansion, and continued extremely high demand for Sotyktu and Camzyos.

Source: https://seekingalpha.com/article/4660486-bristol-myers-squibbs-winning-formula-dividends-m-and-a-and-innovation?source=feed_all_articles